The Industrial Challenge Behind the Cell Therapy Revolution
Over the past decade, cell and tissue therapies have moved from experimental concepts to clinical realities. CAR-T therapies, induced pluripotent stem cells (iPSCs), engineered tissues, organoids, and regenerative medicine approaches are progressively transforming the therapeutic landscape and expanding treatment possibilities for diseases that were previously considered difficult or impossible to address.
However, while biological innovation continues to accelerate, manufacturing remains one of the major limiting factors preventing broader clinical adoption. The challenge is no longer simply to demonstrate therapeutic efficacy. Increasingly, the question facing researchers, clinicians, biotechnology companies, and regulatory authorities is how to reliably produce complex cellular products at clinically relevant scales while maintaining quality, functionality, and reproducibility.
These challenges will be at the heart of the discussions during the 9th Congress of the Société Française de Bio-Ingénierie Cellulaire et Tissulaire (SFBCT 2026), which will bring together experts from academia, hospitals, biotechnology companies, and industrial manufacturing environments to explore the future of advanced therapies.
For Cellura, participating in this event represents an opportunity to contribute to one of the most important scientific and technological discussions currently shaping the field of cell-based medicine.
From Biological Discovery to Bioproduction Excellence
The scientific community has achieved remarkable progress in understanding cellular mechanisms, stem cell biology, immune engineering, and tissue regeneration. Yet translating these discoveries into clinically deployable therapies remains a complex undertaking.
Unlike conventional pharmaceutical products, cellular therapies consist of living biological systems whose characteristics can be profoundly influenced by their environment. Cell phenotype, functionality, differentiation state, viability, and therapeutic performance may all be affected by culture conditions throughout the manufacturing process.
As a result, bioproduction has become a strategic component of therapeutic development rather than a simple downstream operation.
The ability to generate reproducible cell populations is now recognized as a critical determinant of clinical success. Small variations introduced during expansion or differentiation can have significant consequences for product consistency, regulatory compliance, and ultimately patient outcomes.
This reality has driven growing interest in manufacturing technologies capable of preserving cellular integrity while supporting scalability.
The Growing Importance of Process Control in Advanced Therapies
As cell therapy programs move toward commercialization, manufacturing constraints become increasingly visible.
Researchers developing next-generation therapies must simultaneously address several challenges:
- expansion of fragile cell populations without altering phenotype
- maintenance of cellular functionality during scale-up
- reproducibility between batches and production sites
- reduction of process variability
- compliance with increasingly stringent GMP requirements
- control of manufacturing costs
These challenges affect virtually all areas of advanced therapy development, from stem-cell-based products and organoids to immune-cell therapies and engineered tissues.
The issue is particularly relevant for highly sensitive biological systems, where physical culture conditions can significantly influence cellular behavior.
Mechanical forces, oxygen distribution, nutrient availability, aggregate formation, and hydrodynamic conditions all contribute to shaping the biological outcome of a culture process.
Consequently, the future of cell therapy manufacturing increasingly depends on the ability to control not only biological parameters but also the physical environment in which cells are cultivated.
Emerging Technologies Reshaping Cell Production
A growing number of technologies are being developed to address the limitations of conventional cell culture systems.
The industry is moving toward platforms capable of providing:
- improved homogeneity within cultures
- reduced mechanical stress
- better scalability
- simplified process transfer
- enhanced reproducibility
These innovations are particularly important for applications involving:
- induced pluripotent stem cells (iPSCs)
- CAR-T and immune-cell therapies
- organoid production
- regenerative medicine
- tissue engineering
- microcarrier-based manufacturing
The objective is clear: create manufacturing environments that support cell expansion while preserving biological functionality and minimizing unwanted variability.
Such approaches have the potential to accelerate clinical translation, facilitate regulatory approval, and improve accessibility to advanced therapies.
Why SFBCT 2026 Is Particularly Relevant
The themes addressed at SFBCT 2026 perfectly illustrate the transformation currently underway across the fields of cell therapy, regenerative medicine, and tissue engineering. While scientific breakthroughs continue to expand the therapeutic potential of living cells, new challenges are emerging around their translation into robust and clinically deployable products.
Today, progress in regenerative medicine can no longer be considered independently from advances in biomanufacturing. Similarly, innovations in cell production increasingly rely on a deeper understanding of cellular behavior, microenvironmental control, and process engineering. At the same time, the development of more predictive biological models is reshaping how researchers design, evaluate, and scale future therapies.
This growing interconnection between biology, engineering, clinical medicine, and industrial production is redefining the innovation landscape. The success of next-generation therapies will not depend solely on biological discoveries, but also on the ability to develop scalable, reproducible, and economically viable manufacturing strategies.
In this context, SFBCT 2026 represents far more than a scientific congress. It serves as a meeting point for the diverse expertise required to move advanced therapies from the laboratory to real-world clinical applications. By fostering dialogue between researchers, clinicians, engineers, and industrial stakeholders, the event contributes to building the foundations of the future cell therapy ecosystem.
Cellura’s Contribution to the Future of Cell Manufacturing
At SFBCT 2026, Cellura will engage with researchers, clinicians, and industrial stakeholders around a central question:
How can increasingly complex biological systems be expanded and manufactured while preserving their integrity, functionality, and translational potential?
This question is becoming increasingly important as advanced therapies move toward larger patient populations and more demanding production requirements.
Cellura’s work focuses on developing culture environments specifically designed for fragile biological systems, with the objective of improving reproducibility, scalability, and process robustness across research and industrial applications.
By contributing to discussions on bioprocess innovation, low-shear culture strategies, and next-generation cell manufacturing, Cellura aims to participate in the broader effort of transforming promising scientific discoveries into accessible therapeutic solutions.
Looking Ahead
The future of advanced therapies will depend not only on breakthroughs in biology but also on our ability to manufacture living products consistently and efficiently.
As the sector continues to mature, manufacturing technologies will play an increasingly central role in determining which therapies successfully reach patients and achieve widespread adoption.
SFBCT 2026 represents an important opportunity to discuss these challenges collectively and explore new approaches capable of supporting the next generation of cell and tissue therapies.
Cellura looks forward to joining the scientific community in Marseille and contributing to the conversations shaping the future of regenerative medicine, cell therapy, and biomanufacturing.
About the event
More information about SFBCT Congress is available on the official website: https://sfbct.fr/9eme-congres/
For further information or to arrange a meeting:
Email: contact@cellura.io
